Riverside promotes healthcare private equity specialist Philip Borden to general partner

Since joining the firm as a principal in early 2005, Borden has focused on investing opportunities in the healthcare area, including medical technology and equipment, healthcare services, outsourced manufacturing and healthcare tools and diagnostics.

Prior to joining Riverside, he served as an investment professional at Oxford Bioscience Partners and Frazier Healthcare Ventures.

David Belluck, a Riverside general partner, said, 'Over the past four years, Philip's deep experience in healthcare investing has been extremely valuable to the firm and to our portfolio companies. We are excited about Philip expanding his role as a leader within the firm for many years to come.'

Riverside is currently investing its Riverside Fund III fund, with a focus on companies with revenues between $20m and $200m and with $5-25m in EBITDA.

Copyright © 2009 AltAssets